3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Multiple Myeloma
4
Lymphoma
3
Recurrence
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, B-Cell, Marginal Zone
2
Glioma
2
Glioblastoma
2
Brain Neoplasms
2
Solid Tumor
1
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Melanoma
1
Leukemia
1
Gliosarcoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Injections
12
pembrolizumab
11
Nivolumab
9
Paclitaxel
8
senaparib
7
Docetaxel
7
Cisplatin
6
Capecitabine
6
Gemcitabine
5
toripalimab
4
tislelizumab
4
atezolizumab
4
Ipilimumab
4
Carboplatin
4
Bevacizumab
4
sintilimab
3
Rifampin
3
Oxaliplatin
3
Itraconazole
3
130-nm albumin-bound paclitaxel
3
zimberelimab
2
pertuzumab
2
osimertinib
2
ontuxizumab
2
navoximod
2
magrolimab
2
fluzoparib
2
famitinib
2
durvalumab
2
camrelizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Solid Tumor
×
marizomib
×
Clear all
NCT04644107
2020-11-25
Expanded Access for Marizomib
Celgene
No longer available